Screener
Maze Therapeutics MAZE MA — Tax Credit Carryforward Amount
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Maze Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:TaxCreditCarryforwardAmount.
The source filing: Maze Therapeutics’s 10-K, filed March 25, 2026.
- Filed
- Mar 25, 2026, 12:00 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001193125-26-122778
| Line item | December 31, 2025 | Expiration year |
|---|---|---|
| Net operating losses, federal (post-December 31, 2017) | $283,607 | Do not expire |
| Net operating losses, federal (pre-January 1, 2018) | — | 12/31/2037 |
| Net operating losses, state | 2,076 | 2037—2045 |
| Tax credits, federal | 15,362 | 2039—2045 |
| Tax credits, state (CA) | 10,867 | Do not expire |
| Tax credits, state (MA) | 235 | 2034-2038 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Maze Therapeutics's MA — tax credit carryforward amount?
- Maze Therapeutics (MAZE) reported MA — tax credit carryforward amount of $235K in Q4 2025.
- What does MA — tax credit carryforward amount mean?
- This represents the total value of accumulated tax credits that a company can apply to reduce future tax liabilities. These credits are typically generated from research and development activities or prior operating losses and serve as a significant non-cash asset for clinical-stage biopharmaceutical companies. Investors monitor this balance to assess the potential for future tax shielding as the company moves toward commercialization and profitability.
Ask your AI about Maze Therapeutics's ma — tax credit carryforward amount.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude